Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.63 |
| ▸ | HTR3E | A5X5Y0 | 3/20 | 0.58 |
| ▸ | HTR3B | O95264 | 3/20 | 0.58 |
| ▸ | HTR3A | P46098 | 3/20 | 0.58 |
| ▸ | HTR3D | Q70Z44 | 3/20 | 0.58 |
| ▸ | HTR3C | Q8WXA8 | 3/20 | 0.58 |
| ▸ | PNMT | P11086 | 2/20 | 0.56 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | IDO1 | P14902 | 2/20 | 0.50 |
| ▸ | AGXT | P21549 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7753581 | 0.98 | TAAR1 (0.61) | TAAR1HTR3EHTR3BHTR3AHTR3D | |
| Methyl Alcohol SCHEMBL27739961 | 0.96 | TAAR1 (0.59) | TAAR1HTR3EHTR3BHTR3AHTR3D | |
| Chlorobenzene SCHEMBL10775138 | 0.94 | TDP1 (0.58) | TAAR1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL82224 | 0.87 | HTR3E (0.59) | TAAR1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL10786326 | 0.86 | PDE4B (0.52) | TAAR1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL12050856 | 0.85 | TAAR1 (0.74) | TAAR1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL1047900 | 0.85 | HTR3E (0.58) | TAAR1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL7740676 | 0.84 | HTR3E (0.56) | TAAR1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL1046534 | 0.84 | HTR3E (0.56) | TAAR1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL3030059 | 0.84 | HTR3E (0.56) | TAAR1HTR3EHTR3BHTR3AHTR3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 533 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119491240-A | Method for preparing benzyl carboxylic acid compound by taking carbon dioxide as raw material | 哈尔滨工业大学（深圳） | 2025-02-21 | — | — | CN | claimed |
| CN-118991174-A | Metal surface phenolic foam sandwich board for building engineering | 山东北理华海复合材料有限公司 | 2024-11-22 | — | — | CN | claimed |
| CN-113333018-A | Preparation method and application of supported catalyst for preparing halogenated styrene | 中触媒新材料股份有限公司 | 2021-09-03 | — | — | CN | claimed |
| CN-106811432-B | Erysivelum pratense and application thereof in preparation of (R) -3-chlorobenzene ethanol | 浙江医药高等专科学校 | 2020-04-28 | — | — | CN | claimed |
| CN-106811432-A | A kind of oerskovia turbata and the application in (R) 3 chlorophenethylol is prepared | 浙江医药高等专科学校 | 2017-06-09 | — | — | CN | claimed |
| CN-106046281-A | FUNCTIONALIZED KETONE-ALDEHYDE CONDENSATION RESINS | 赢创德固赛有限公司 | 2016-10-26 | — | — | CN | claimed |
| CN-104450801-A | Application of double-enzyme method to asymmetric preparation of (R)-2-chloro-1-(3-chlorphenyl) ethyl alcohol | UNIV JIANGNAN | 2015-03-25 | — | — | CN | claimed |
| US-6989052-B1 | Phase change ink printing process | XEROX CORPORATION (US) | 2006-01-24 | — | — | US | claimed |
| US-20060004123-A1 | PHASE CHANGE INK PRINTING PROCESS | XEROX CORPORATION | 2006-01-05 | — | — | US | claimed |
| US-20050137220-A1 | Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors | PHARMACIA CORPORATION (US) | 2005-06-23 | — | — | US | claimed |
| US-20050101623-A1 | Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors | PHARMACIA CORPORATION (US) | 2005-05-12 | — | — | US | claimed |
| EP-3704094-B1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20260035381-A1 | COMPOUNDS AND COMPOSITIONS AND USES THEREOF | SUMITOMO PHARMA AMERICA, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| CN-116514880-B | Novel PNNO and PNNN chiral tetradentate ligand and application thereof in asymmetric hydrogenation | 凯特立斯（深圳）科技有限公司 | 2025-06-10 | — | — | CN | disclosed |
| US-20250122188-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2025-04-17 | — | — | US | disclosed |
| EP-0162208-A2 | Novel N-substituted 3,4-dihydropyrimidine derivatives, processes for preparing them and pharmaceutical compositions | SUNTORY KABUSHIKI KAISHA, also known as SUNTORY LTD. (JP) | 1985-11-27 | — | — | EP | disclosed |
| EP-0146053-A2 | Chemical process for preparing antibiotic L 17392 (Deglucoteicoplanin) and its salts | GRUPPO LEPETIT S.p.A. (IT) | 1985-06-26 | — | — | EP | disclosed |
| EP-0025598-B1 | THE USE OF 2-PHENYLTETRALIN DERIVATIVES, OR HETEROCYCLIC ANALOGUES, IN MEDICINE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | THE WELLCOME FOUNDATION LIMITED (GB) | 1984-08-01 | — | — | EP | disclosed |
| EP-0096770-A1 | Process for producing olefin polymers | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1983-12-28 | — | — | EP | disclosed |
| EP-0025598-A1 | The use of 2-phenyltetralin derivatives, or heterocyclic analogues, in medicine and pharmaceutical compositions containing them | THE WELLCOME FOUNDATION LIMITED (GB) | 1981-03-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260035381-A1 | COMPOUNDS AND COMPOSITIONS AND USES THEREOF | ADH1C, HTR6, CNR1 | TAAR1 97/4885HTR3E 211/4885HTR3B 88/4885 |
| US-20250122188-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | TAAR1 2815/4885HTR3E 2823/4885HTR3B 1795/4885 |
| US-20050137220-A1 | Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors | MAPKAPK2, MAP4K2, MAP3K2 | TAAR1 2305/4885HTR3E 3087/4885HTR3B 1005/4885 |
| US-20050101623-A1 | Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors | MAP4K2, MAPKAPK2, MAP3K2 | TAAR1 2784/4885HTR3E 2702/4885HTR3B 906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.